<DOC>
	<DOCNO>NCT00014261</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PEG-interferon alfa-2B may interfere growth cancer cell . Combining temozolomide PEG-interferon alfa-2B may effective treatment advance solid tumor . PURPOSE : Phase I trial study effectiveness combine temozolomide PEG-interferon alfa-2B treat patient advance solid tumor .</brief_summary>
	<brief_title>Temozolomide Plus PEG-Interferon Alfa-2B Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety tolerability temozolomide PEG-interferon alfa-2b patient advanced refractory solid tumor chemotherapy-naive advanced cancer . - Determine maximum tolerate dose ( MTD ) dose-limiting toxicity regimen patient population . - Determine pharmacokinetics PEG-interferon alfa-2b MTD administer temozolomide patient population . - Determine anti-tumor activity regimen patient . OUTLINE : This dose-escalation study . Patients receive oral temozolomide day 1-7 15-21 PEG-interferon alfa-2b subcutaneously day 1 , 8 , 15 , 22 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 1-9 patient receive escalate dos temozolomide PEG-interferon alfa-2b maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A maximum 24 patient accrue study .</detailed_description>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced solid tumor refractory standard therapy OR Histologically confirm chemotherapynaive advanced cancer curative therapy high priority palliative chemotherapy exist Brain metastasis allow No bone marrow involvement tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,500/mm^3 AND/OR Platelet count great 100,000/mm^3 Hepatic : ALT AST less 3 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) No autoimmune hepatitis Renal : Creatinine le 2.5 time ULN Cardiovascular : No severe coronary artery disease No congestive heart failure Pulmonary : No severe chronic obstructive pulmonary disease Gastrointestinal : No frequent vomit No medical condition would interfere oral medication intake ( e.g. , partial bowel obstruction , partial intestinal bypass , external biliary diversion ) Other : No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No known suspect hypersensitivity imidazotetrazin , interferon alfa , excipient vehicle include formulation delivery system study drug No history autoimmune disease No preexisting severe psychiatric condition history severe psychiatric disorder ( include suicidal ideation attempt ) No lifethreatening condition severe preexist condition No uncontrolled thyroid abnormalities No nonmalignant systemic disease No active uncontrolled infection HIV negative No AIDSrelated illness Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior biologic agent ( e.g. , bispecific antibody , interleukin2 , interferon ) recover ( exclude alopecia ) No prior allogeneic , syngeneic , autologous bone marrow stem cell transplantation No concurrent biologic therapy No concurrent colony stimulate factor epoetin alfa prevention myelotoxicity Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas , melphalan , mitomycin ) recover ( exclude alopecia ) No prior highdose chemotherapy stem cell transplantation No 3 prior chemotherapy regimens No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 6 week since prior widefield radiotherapy least 25 % bone marrow ( e.g. , pelvic radiotherapy ) More 6 week since prior strontium chloride Sr 89 samarium Sm 153 lexidronam pentasodium Recovered prior radiotherapy ( exclude alopecia ) No concurrent radiotherapy Surgery : At least 4 week since prior major surgery At least 1 week since prior minor surgery Other : At least 4 week since prior investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>